Clinical Trial: Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07681323) titled 'Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer' on June 26.

Brief Summary: This multicenter, prospective observational cohort study aims to investigate the impact of ctDNA level and key actionable gene mutation status on prognosis and treatment response in patients with advanced HR+/HER2- breast cancer.

Study Start Date: June 30

Study Type: OBSERVATIONAL

Condition: Advanced Breast Cancer

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Geneplus-Beijing Co. Ltd.

Disclaimer: Curated by HT Syndication....